Clinical Trial Update: PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of PTM-101 for pancreatic ductal adenocarcinoma and related locally advanced or borderline resectable disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Adenocarcinoma
• Pancreatic Adenocarcinoma
• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• PTM-101

Snippet

Sponsor: PanTher Therapeutics | Conditions: Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 1 | Status: RECRUITING